Jennison Associates
IBB icon

Jennison Associates’s iShares Biotechnology ETF IBB Stock Holding History

Jennison Associates’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-5,643
Closed -$571K – 726
2014
Q4 		$571K Buy
+5,643
New +$548K ﹤0.01% 687

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
CM
Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Jennison Associates's IBB Position: Q3 2017 in Review

Jennison Associates sold out of iShares Biotechnology ETF (IBB) in Q3 2017, closing a stake of 1,950 shares — an estimated $208K sold.

Jennison Associates first reported a position in IBB in Q2 2017 and held it in 1 quarter. The position peaked at $202K in Q2 2017. 584 funds tracked by Wall St. Rank hold IBB as of Q3 2017.

  • Jennison Associates reported no remaining iShares Biotechnology ETF position as of Q3 2017 after selling out during the quarter.
  • Jennison Associates sold 1,950 iShares Biotechnology ETF shares in Q3 2017, an estimated $208K.
  • Jennison Associates first reported a position in iShares Biotechnology ETF in Q2 2017 and held it in 1 quarter.
  • Jennison Associates's iShares Biotechnology ETF position peaked at $202K in Q2 2017.
  • 584 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2017.

Based on Jennison Associates's 13F filing for Q3 2017, filed 3 Nov 2017.